This protocol addresses chronic liver failure in patients with liver cirrhosis who present for the first time with grade 2 (moderate) uncomplicated ascites — a well-defined clinical threshold that calls for a specific, evidence-based first-line strategy.
The underlying condition is liver cirrhosis. The defining event is a first episode of grade 2 (moderate) uncomplicated ascites — clinically detectable fluid accumulation without complications such as spontaneous bacterial peritonitis or hepatorenal syndrome.
This scenario is distinct from refractory ascites or recurrent episodes and warrants a focused initial approach aimed at controlled fluid reduction.
The first-line strategy combines moderate dietary sodium restriction with an anti-mineralocorticoid drug as the primary pharmacological agent. Doses are titrated stepwise based on clinical response.
The complete regimen — including specific dose escalation steps, monitoring intervals, and the criteria that define treatment response — is available in the full protocol.
The target is a body weight reduction of at least 2 kg per week. The acceptable maximum daily weight loss differs depending on whether the patient has oedema. Attainment of these targets determines whether the current approach is continued or escalated.
DOI: 10.1016/j.jhep.2018.03.024
A moderate restriction of sodium intake (80–120 mmol/day, corresponding to 4.6–6.9 g of salt) is recommended in patients with moderate, uncomplicated ascites (I;1).
Patients with the first episode of grade 2 (moderate) ascites should receive an anti-mineralocorticoid drug alone, starting at 100 mg/day with stepwise increases every 72 h (in 100 mg steps) to a maximum of 400 mg/day if there is no response to lower doses (I;1).
During diuretic therapy a maximum weight loss of 0.5 kg/day in patients without oedema and 1 kg/day in patients with oedema is recommended (II-2;1).
View source ↗